CYTR Share Price

Open 0.42 Change Price %
High 0.42 1 Day 0.01 2.50
Low 0.39 1 Week 0.01 2.50
Close 0.41 1 Month -0.01 -2.38
Volume 651876 1 Year -2.05 -83.33
52 Week High 3.66
52 Week Low 0.36
CYTR Important Levels
Resistance 2 0.44
Resistance 1 0.43
Pivot 0.41
Support 1 0.39
Support 2 0.38
NASDAQ USA Most Active Stocks
MU 28.43 7.40%
MU 28.43 7.40%
MU 28.43 7.40%
FNFG 10.18 -0.20%
FTR 2.09 7.73%
FTR 2.09 7.73%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 200.00%
AMCF 0.10 100.00%
VALV 0.04 100.00%
LOCM 0.09 50.00%
BGMD 0.08 33.33%
ESMC 0.12 33.33%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

CytRx Corporation (NASDAQ: CYTR)

CYTR Technical Analysis 5
As on 24th Mar 2017 CYTR Share Price closed @ 0.41 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.01 & Strong Sell for SHORT-TERM with Stoploss of 0.42 we also expect STOCK to react on Following IMPORTANT LEVELS.
CYTR Target for March
1st Target up-side 0.47
2nd Target up-side 0.5
3rd Target up-side 0.53
1st Target down-side 0.39
2nd Target down-side 0.36
3rd Target down-side 0.33
CYTR Other Details
Segment EQ
Market Capital 47314736.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.cytrx.com
CYTR Address
CYTR
11726 San Vicente Boulevard
Suite 650
Los Angeles, CA 90049
United States
Phone: 310-826-5648
Fax: 310-826-6139
CYTR Latest News
Interactive Technical Analysis Chart CytRx Corporation ( CYTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on CytRx Corporation
CYTR Business Profile
CytRx Corporation (CytRx) is a biopharmaceutical research and development company specializing in oncology. The Company's oncology pipeline includes three programs in clinical development for cancer indications: INNO-206, tamibarotene and bafetinib. INNO-206 is the Company's tumor-targeted doxorubicin conjugate. On May 13, 2011, the Company sold all pre-clinical and clinical data, intellectual property rights and other assets relating to those compounds to Orphazyme ApS. During the year ended December 31, 2011, the Company sold of its 19% interest in SynthRx to ADVENTRX Pharmaceuticals.